The global cell line development market is growing rapidly; it is estimated to be worth USD 1.01 billion in 2023 and is expected to reach USD 4.5 billion by 2035. It is anticipated to grow at a higher ...

Insourcing cell-line development has helped a fast-growing antibody manufacturer to deliver process improvements and strengthen communication with their contract manufacturer, according to Genmab, ...

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...

Think about your favorite medicine. Maybe it is a vaccine or a powerful antibody. Have you ever wondered how it is made? It does not come from a chemical plant. It often comes from living cells.

EZ-editor™ platform, large-scale cell resources, and standardised workflows support faster and more reliable knockout ...

TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...

Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...

Discover how to streamline your cell line development process for recombinant protein and monoclonal antibody production with this in-depth eBook. Whether you're working with CHO, HEK293, or hybridoma ...

Samsung Biologics said Monday it has launched in-house master cell bank production and vector construction services, strengthening its contract development orga ...

If you’ve ever had to pause a promising experiment while waiting on titer results, you’re not alone. In many labs, samples come off the bioreactor only to sit in line for ELISA or HPLC - and decisions ...

Biologics and cell therapy programs face increasing pressure to generate high-quality cell lines and physiologically relevant 3D models, faster and with greater reproducibility. Integrated automation ...

Cell line development continues to face technical and operational hurdles in transfection, clone selection, and media optimization. Manual screening, extended culture timelines, and fragmented data ...